Repros Therapeutics

Repros Therapeutics — Investor Presentation (February 2010)

35 slides from Repros Therapeutics's investor presentation, Feb 8, 2010

  1. Slide 1: Repros Therapeutics

    Slide 1: Repros Therapeutics

    Reprds THERAPEUTICS IN Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Repros Strategy

    Slide 2: Repros Strategy

    Repros Strategy Focus on small molecule therapeutics for hormonal and reproductive system disorders that exhibit significant market potential and that are currently underserved Out-license or Partner Technologies for Marketing Consider Merger or Acquisition Late stage development of highly different

  3. Slide 3: Androxal Summary

    Slide 3: Androxal Summary

    Androxal Summary » Type C meeting held on January 25, 2010 ~ Discussed indication for treatment of hypogonadism in men wishing to preserve fertility during treatment » New IND to Endocrine Division of FDA to study impact of anti-estrogens on metabolism of men with sub optimal treatment of Type II di

  4. Slide 4: FDA Response to Repros Briefing Package Proposed Indication

    Slide 4: FDA Response to Repros Briefing Package Proposed Indication

    FDA Response to Repros Briefing Package Proposed Indication “for the treatment of secondary hypogonadism in men wishing to preserve fertility while undergoing therapy” “Division Response: We cannot currently agree with your proposed indication for the following reasons: » The patient population has

  5. Slide 5: Type C Meeting Outcome

    Slide 5: Type C Meeting Outcome

    Type C Meeting Outcome January 25, 2010 » Discussion focused on defining patient population for whom Androxal is intended » FDA was uncomfortable with broad term “Secondary Hypogonadism” » FDA requested Repros to conduct a literature search to support the notion that exogenous testosterone administr

  6. Slide 6: Repros Androxal Indication

    Slide 6: Repros Androxal Indication

    Repros Androxal Indication Statement Androxal is intended for the treatment of men with low testosterone wishing to preserve fertility during treatment for their condition and who do not suffer from testicular failure’. Men responsive to Androxal treatment will exhibit an increase in luteinizing hor

  7. Slide 7: Sampling of Repros Literature Review Supporting Notion

    Slide 7: Sampling of Repros Literature Review Supporting Notion

    Sampling of Repros Literature Review Supporting Notion That Exogenous Testosterone Suppresses Fertility » Clinical Practice Guidelines from the Endocrine Society ~ Reduced sperm production and infertility is a potential adverse effect of testosterone replacement in adult men with androgen deficiency

  8. Slide 8: Repros Study ZA-201

    Slide 8: Repros Study ZA-201

    Repros Study ZA-201 Impact of Treatment on Sperm Counts “Any future trials for such an indication would need to demonstrate that enclomiphene is superior to testosterone and that testosterone is inferior to placebo with regards to the effect on semen analysis.” 400 350 4— Highest morning T in respon

  9. Slide 9: Previous Androxal Previous Experience

    Slide 9: Previous Androxal Previous Experience

    Previous Androxal Previous Experience ZA-003 n=200 Month 6 Morning Total Testosterone vs Pbo<0.001 vs Androgel=0.001, vs Pbo=0.0016 vs Pbo=0.0136 3 2 300 = IE 200 100 0 12.5mg Androxal 25mg Androxal Androgel Placebo

  10. Slide 10: A Large Patient Population Fits the Intended Use

    Slide 10: A Large Patient Population Fits the Intended Use

    A Large Patient Population Fits the Intended Use Hormonal Criteria for Androxal Number of Subjects Screened in ZA-003 0 ed Screened Screened Subjects Subjects in-study LH>30 LH>15

  11. Slide 11: Over 30% of Men Studied Were Under the Age of 40

    Slide 11: Over 30% of Men Studied Were Under the Age of 40

    Over 30% of Men Studied Were Under the Age of 50 % of Men in Study by Age 41<30 31-40 141-50 51-60 4161-70 1%

  12. Slide 12: New IND Submitted

    Slide 12: New IND Submitted

    New IND Sumitted Impact of Androxal on Men with Suboptimal Treatment of Type II Diabetes » Retrospective analysis of men with elevated fasting glucose (FPG) levels suggested reduction of FPG post administration of Androxal » Neither placebo nor testosterone exhibited similar effects » Proof of conce

  13. Slide 13: Androxal Impact on Fasting Glucose

    Slide 13: Androxal Impact on Fasting Glucose

    Androxal Impact on Fasting Glucose Retrospective Analysis on Subjects with Glucose >105 mg/dL «en | e_P value is change from baseline ® 150 3 p=0.019 p=0.77 5 140 rc} a ; =! 130 Baseline ne] > On Drug £ 120 110 100 T T 12.5mg 25mg Androgel Placebo Androxal Androxal n=19 n=21 n=17 n=20

  14. Slide 14: ZA-003 T2D Responder Analysis

    Slide 14: ZA-003 T2D Responder Analysis

    ZA-003 T2D Responder Analysis Month 3-6 Compared to Baseline in Men with FPG > 126 mg/dL Androxal vs placebo p=0.002 20 i Androxal vs Androgel p=0.027 15 ™ Non Responders 10 Responders 5 0 T 1 Androxal Placebo Testim Responders were those who demonstrated at least two decreases >10 mg/dL in fasting

  15. Slide 15: Median Change in Fasting Plasma Glucose Levels from Baseline

    Slide 15: Median Change in Fasting Plasma Glucose Levels from Baseline

    Median Change in Fasting Plasma Glucose Levels from Baseline 10 5 , 1 2 (0 — —| = B 5 Androxal Placebo Androgel & -10 = 15 Androxal v Placebo p=0.035 a 2 Androxal v Androgel p=0.018 © -20 | Roughly 10 subjects per group. g Androxal is the total of both doses O -25 -30 & a

  16. Slide 16: Proellex Summary

    Slide 16: Proellex Summary

    Proellex® Summary + Appeared well tolerated at all doses; clinical investigators very positive about tolerability of Proellex® in their patients + Low (4%) discontinuations due to side effects while study underway + Potential for breakthrough bleeding significantly reduced by incorporating “off- dru

  17. Slide 17: FDA Request for Data Necessary to Lift Clinical Hold

    Slide 17: FDA Request for Data Necessary to Lift Clinical Hold

    FDA Request for Data Necessary to Lift Clinical Hold » FDA concerned that safe and effective dose will be difficult to achieve » FDA noted that doses for new studies should not encroach upon the 95% confidence level of exposure of clearly toxic doses (50mg?)

  18. Slide 18: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Slide 18: Key Symptom Driving Women to Seek Therapy for Uterine Fibroids

    Key Symptom Driving Women to Seek Therapy for Uterine Fibroids Excessive Menstrual Bleeding Days of Vaginal Bleeding Over 4 Months 00 - Menorrhagia=PBAC>80 Spotting WLight M Moderate Hl Heavy) a P<0.0001 Days of " ‘ ays of Bleeding Over ° 4Mo, 40 i P<0.05 on 6 ° il [a | 25 % $0 ~—_Lupron Placebo BL

  19. Slide 19: Proellex Produces Significant Clinical Benefit

    Slide 19: Proellex Produces Significant Clinical Benefit

    Proellex Produces Significant Clinical Benefit Resulting in Substantially Asymptomatic Uterine Fibroids UFSQOL Uterine Fibroid Symptom Survey US Phase IIb (n=127) OPlacebo 12.5mgProellex 25 mg Proellex creme 90 80 w 70 ° 60 pvs placebo 9 < 0.0001 for both ® 50 Noses P vs placebo 3 40 < 0.005 for bot

  20. Slide 20: Key Symptom Driving Women to Seek Therapy for Endometriosis

    Slide 20: Key Symptom Driving Women to Seek Therapy for Endometriosis

    Key Symptom Driving Women to Seek Therapy for Endometriosis Pelvic Abdominal Pain % Pain Free Days — 6 Months of Treatment 100 * Fewer mean days of pain with 50mg Proellex (higher percentage of gm pain free days than with fe Lupron) p< 0.05 £50 40 + Lupron not statistically different from 12.5mg and

  21. Slide 21: Baseline vs Last Days

    Slide 21: Baseline vs Last Days

    BASELINE vs LAST 28 DAYS DYSMENORRHEA 40 Last 28 Days ~ oO 35 OPlacebs g oD jacebo o H 30 160 225mg & ee GPlacebo cy snes 3 B20 @25 = COTE o mg o = a ™50 mg & 100 6 15 © go 25 & 50 S 6 mg £ 10 25mg vs pbo x «(80 g DEO 40 25 mg vs pho a 5 50mg vs pbo 20 Ll] aaaie p=0.97 3 o LL ball | £09 set0 25850 v

  22. Slide 22: % of Analgesic Free Patients

    Slide 22: % of Analgesic Free Patients

    % of Analgesic Free Patients Comparison with Baseline 70 60 50 % of Patients Not Taking 4° Analgesics 30 20 10 0 OPlacebo 25mg Proellex 50mg Proellex Baseline Last 28 days

  23. Slide 23: ZPU-003 Phase II Uterine Fibroid Study

    Slide 23: ZPU-003 Phase II Uterine Fibroid Study

    ZPU-003 Phase II Uterine Fibroid Study Percent of Women Continuing to Experience Menstrual Cycles c 80 o € 60 OPlacebo 2 aProellex 12.5 mg 5 40 |Proellex 25mg 3s 20 0 i= 100% 66% 50% 33% 0% % of Potential Cycles Where Menses Was Observed The underlying physiologic outcome of an antiprogestin is to i

  24. Slide 24: Hormonal Events Associated with the Menstrual Cycle

    Slide 24: Hormonal Events Associated with the Menstrual Cycle

    Hormonal Events Associated with the Menstrual Cycle Menstrual Cycle Ovarian Cycle Ov Proellex induces a hormonal environment _ consistent with the early follicular phase

  25. Slide 25: All Doses of Proellex Produce Similar Hormonal Pattern

    Slide 25: All Doses of Proellex Produce Similar Hormonal Pattern

    All Doses of Proellex Produce Similar Hormonal Pattern 10 Median Serum LH (miU/mL) oN bo @ Baseline Month 3 Month 6 [[lupron 012.5 mg Proelex 825 mg Prosllex 950 mg Prose]

  26. Slide 26: FDA Guidance For Liver Enzyme Elevation Characterization as SAE

    Slide 26: FDA Guidance For Liver Enzyme Elevation Characterization as SAE

    FDA Guidance For Liver Enzyme Elevation Characterization as SAE 1. LFTs 28 x ULN ° 2. LFTs 2 5 x ULN for 2 consecutive weeks «3 LFTs 2 3 x ULN + Bilirubin 2 x ULN 4, LFTs 2 3 x ULN + clinical signs or symptoms (nausea; jaundice; etc.)

  27. Slide 27: Proellex Liver Enzyme Associated SAEs

    Slide 27: Proellex Liver Enzyme Associated SAEs

    Proellex Liver Enzyme Associated SAEs No Deaths No Transplants, ‘One Subject Received Oral Treatment Allin Follow-up Data Base Have returned to Normal % of Subjects 12.5mg 25mg 50mg Dose of Proellex

  28. Slide 28: Overall Summary of Any Abnormal Liver Function Tests

    Slide 28: Overall Summary of Any Abnormal Liver Function Tests

    Percent of Patients Overall Summary of Any Abnormal Liver 18 16 14 12 10 oN FF ® & Function Tests During Treatment Period N=190 Placebo! 12.5mg 25mg 50 mg Active Control Dose O> ULN G> 1.5 x ULN G>3xULN @>5xULN @>8x ULN m> 10 x ULN m> 20x ULN

  29. Slide 29: Steady State Proellex Human PK Data

    Slide 29: Steady State Proellex Human PK Data

    STEADY STATE PROELLEX HUMAN Pk DATA Day 28 Proellex Blood Levels ng/ml) iS 8 Oo Total Proellex S ts} f=) 0 10 20 30 Hours After Administration

  30. Slide 30: Comparison of 95% Confidence Level of Parent Compound Exposure

    Slide 30: Comparison of 95% Confidence Level of Parent Compound Exposure

    Comparison of 95% Confidence Level of Parent Compound Exposure at Different Doses of Proellex Mean Trough Mean Cmax Concentrations (ng/ml) Concentrations (ng/ml) 600 2000 pa 1500 ff 400 300 1000 | 200 so |} —__ — 100 0 0 12.5mg 25mg 50mg P value 12.5 mg vs 25 mg = 0.024 12.5mg 25mg 50mg P value 12.5

  31. Slide 31: Endometrial Biopsy Diagnoses by Dose

    Slide 31: Endometrial Biopsy Diagnoses by Dose

    2' Dx Baseline | 12.5mg 25mg 50mg | Dosep Atrophic 0.0 5.8 3.9 3.7 0.829 Inactive 11.1 46.4 51.3 81.1 0.002 Proliferative 8.5 13.0 5.1 0 0.052 Disordered Proliferative 11.8) 17.4 25.6 0 0.012 Secretory 76.5 13.0 9.0 0 0.138 Menstrual 1183 0 0 3.7 0.065 Other 1.3 44 5.1 TA 0.831 Total Passes (cases x

  32. Slide 32: Repros Proellex Strategy: Going Forward

    Slide 32: Repros Proellex Strategy: Going Forward

    Repros Proellex Strategy “Going Forward” » Lift Clinical Hold — Demonstrate significantly reduced exposure and risk at lower doses — Conduct short duration (45 days) low dose study to demonstrate effectiveness (induction of amenorhea) » Commence Alternate Route of Administration Studies for Current

  33. Slide 33: Repros Stock Performance

    Slide 33: Repros Stock Performance

    Repros Stock Performance

  34. Slide 34: Repros Projected Net Income, Financing & Impact on Shareholder Equity

    Slide 34: Repros Projected Net Income, Financing & Impact on Shareholder Equity

    Repros Projected Net Income, Financing & Impact on Shareholder Equity NetIncome Financing Shareholder Equity 6000 rr 50005155 GS 4000 Actual Financing October 2009 S 2000 i 2 x 0 ® 5000 -800 -879 -670 -4000 -6000 ;— —— a ‘ -Shareholder equity of $2.5 million -8000 +$1 share price 8285 -Criteria must

  35. Slide 35: Repros Summary

    Slide 35: Repros Summary

    Repros Summary » Androxal Poised to Move Toward Phase III Efficacy Studies Pending FDA Agreement on Indication » Phase Ila Study for Androxal in Type II Diabetes Ready to Begin » Proposal to Lift clinical Hold on Proellex to be Submitted in Q1 » Repros Must Raise Capital Now in Order to Move Forward

Source: SEC EDGAR · 8-K filed Feb 8, 2010

More decks from Repros Therapeutics